Literature DB >> 762788

Toxic effects of isoniazid in tuberculosis chemoprophylaxis. Role of biochemical monitoring in 1,000 patients.

R B Byrd, B R Horn, D A Solomon, G A Griggs.   

Abstract

One thousand patients receiving isoniazid chemoprophylaxis were prospectively followed up to assess the value of liver function monitoring plus monthly clinical evaluation. Two hundred twenty-two (22.2%) of the patients had at least one elevated SGOT level during the course of treatment, and 47 asymptomatic persons had isoniazid therapy discontinued because of consistent elevations greater than five times normal. Another 17 had symptoms in association with elevated SGOT levels, and therapy was stopped in these patients as well. No patient became seriously ill, and there were no deaths. Biochemical monitoring should be done routinely in patients receiving isoniazid chemoprophylaxis to avoid the development of irreversible hepatic reactions.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 762788

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  23 in total

1.  Isoniazid preventive therapy, hepatitis C virus infection, and hepatotoxicity among injection drug users infected with Mycobacterium tuberculosis.

Authors:  P Sadaphal; J Astemborski; N M Graham; L Sheely; M Bonds; A Madison; D Vlahov; D L Thomas; T R Sterling
Journal:  Clin Infect Dis       Date:  2001-10-12       Impact factor: 9.079

Review 2.  Hepatotoxicity from antituberculous therapy in the elderly: a systematic review.

Authors:  Jennifer D Hosford; Michael E von Fricken; Michael Lauzardo; Myron Chang; Yunfeng Dai; Jennifer A Lyon; John Shuster; Kevin P Fennelly
Journal:  Tuberculosis (Edinb)       Date:  2014-12-18       Impact factor: 3.131

3.  Antituberculous therapy in children.

Authors:  V Seth
Journal:  Indian J Pediatr       Date:  1986 Mar-Apr       Impact factor: 1.967

Review 4.  Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status.

Authors:  F Durand; G Jebrak; D Pessayre; M Fournier; J Bernuau
Journal:  Drug Saf       Date:  1996-12       Impact factor: 5.606

5.  Antibiotics and the liver.

Authors: 
Journal:  Br Med J       Date:  1980-06-21

6.  Slow N-acetyltransferase 2 genotype contributes to anti-tuberculosis drug-induced hepatotoxicity: a meta-analysis.

Authors:  Haijian Du; Xiaorong Chen; Yi Fang; Ouyang Yan; Hong Xu; Li Li; Weifeng Li; Wenjie Huang
Journal:  Mol Biol Rep       Date:  2013-01-01       Impact factor: 2.316

7.  Increased incidence of liver enzymes abnormalities in patients treated with isoniazid in combination with disease modifying and/or biologic agents.

Authors:  Josiane Bourré-Tessier; Mireia Arino-Torregrosa; Denis Choquette
Journal:  Clin Rheumatol       Date:  2014-02-21       Impact factor: 2.980

8.  Fatal isoniazid-induced hepatitis. Its risk during chemoprophylaxis.

Authors:  S R Salpeter
Journal:  West J Med       Date:  1993-11

9.  Late effects following isoniazid therapy.

Authors:  J D Boice; J F Fraumeni
Journal:  Am J Public Health       Date:  1980-09       Impact factor: 9.308

10.  Fulminant hepatitis during treatment with rifampicin, pyrazinamid and ethambutol.

Authors:  W M van Aalderen; H Knoester; K Knol
Journal:  Eur J Pediatr       Date:  1987-05       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.